<DOC>
	<DOCNO>NCT01381900</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , efficacy addition canagliflozin relative addition placebo patient inadequate glycemic control metformin alone combination sulphonylurea .</brief_summary>
	<brief_title>A Efficacy , Safety , Tolerability Study Canagliflozin Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Metformin Alone Combination With Sulphonylurea</brief_title>
	<detailed_description>This double-blind ( neither study staff patient know identity treatment assign ) study canagliflozin Chinese Asian adult patient Type 2 Diabetes Mellitus ( T2DM ) inadequate glycemic control metformin alone combination sulphonylurea ( SU ) randomize ( assigned 1 3 treatment chance ) receive addition treatment canagliflozin 100 mg daily , canagliflozin 300 mg daily , match placebo capsule ( placebo treatment identical appearance canagliflozin contain active drug ) . All patient take orally ( mouth ) 1 single-blind placebo capsule daily first meal day 2 week ( last dose single-blind placebo take day baseline ( Day 1 ) visit . On Day 1 , patient take orally , daily 1 capsule canagliflozin 100 mg , canagliflozin 300 mg , placebo first meal day 18 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients T2DM inadequate glycemic control metformin monotherapy metformin combination SU protocolspecified dos HbA1c &gt; =7.0 % &lt; =10.5 % Week 2 eligible enrollment study . History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy Has repeat ( ie , 2 1week period ) fast plasma glucose ( FPG ) and/or fast selfmonitored blood glucose ( SMBG ) measurement &gt; =270 mg/dL ( 15 mmol/L ) pretreatment phase , despite reinforcement diet exercise counsel History severe hypoglycemic episode within 6 month screen History current illness consider clinically significant investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>